NCT06376045Not yet recruiting
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
AmgenPhase 2ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Asthma
- Drug/Device/Intervention
- Rocatinlimab
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Amgen
Timeline & enrollment
- Phase
- Phase 2
- Start date
- May 10, 2024
- End date
- Oct 02, 2026
- Enrollment
- 428 participants
Primary outcome
Annualized Asthma Exacerbation Rate (AAER) During the Blinded Treatment Period
Summary
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing
 asthma exacerbations.
ICD-10 classifications
AsthmaAsthma, unspecifiedNonallergic asthmaMixed asthmaPredominantly allergic asthma
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06376045
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06376045 through Pure Global AI's free database. This Phase 2 trial is sponsored by Amgen and is currently Not yet recruiting. The study focuses on Asthma. Target enrollment is 428 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.